Checkpoint immunotherapy: good for cancer therapy, bad for rheumatic diseases

Affiliations

¹ Department of Rheumatology/Immunology, Cleveland Clinic, Cleveland, Ohio, USA.
² Department of Hematology and Oncology, Cleveland Clinic, Cleveland, Ohio, USA.

Editorial

Leonard Calabrese et al. Ann Rheum Dis. 2017 Jan.

. 2017 Jan;76(1):1-3.

doi: 10.1136/annrheumdis-2016-209782. Epub 2016 Aug 26.

¹ Department of Rheumatology/Immunology, Cleveland Clinic, Cleveland, Ohio, USA.
² Department of Hematology and Oncology, Cleveland Clinic, Cleveland, Ohio, USA.

No abstract available

Keywords: Autoimmune Diseases; DMARDs (biologic); Inflammation.

Comment on

Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab.
Cappelli LC, Gutierrez AK, Baer AN, Albayda J, Manno RL, Haque U, Lipson EJ, Bleich KB, Shah AA, Naidoo J, Brahmer JR, Le D, Bingham CO 3rd. Cappelli LC, et al. Ann Rheum Dis. 2017 Jan;76(1):43-50. doi: 10.1136/annrheumdis-2016-209595. Epub 2016 Jun 15. Ann Rheum Dis. 2017. PMID: 27307501 Free PMC article.